Literature DB >> 23825914

Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.

Ping Yang1, Qi Zhu, Fuqiang Jiang.   

Abstract

Bevacizumab, an angiogenesis inhibitor, is a recombined humanized monoclonal antibody against vascular endothelial growth factor and a promising therapeutic option for angiosarcoma management. This is a case report and review of the literature using bevacizumab and combination chemotherapy for angiosarcoma. The understanding of the effectiveness of combined therapy of bevacizumab and chemotherapy agents is still limited. The benefits of bevacizumab treatment for angiosarcoma will need to be weighed against the risks of venous thromboembolism in this population.

Entities:  

Keywords:  Angiosarcoma; angiogenesis inhibitor; bevacizumab; chemotherapy; combination therapy

Year:  2013        PMID： 23825914      PMCID： PMC3696716          DOI： 10.3978/j.issn.1000-9604.2013.06.09

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


  26 in total

1.  Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.

Authors:  Christopher K Fuller; John A Charlson; Steven K Dankle; Thomas J Russell
Journal:  J Am Acad Dermatol       Date:  2010-10       Impact factor: 11.527

2.  Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.

Authors:  A Rosen; S Thimon; D Ternant; M C Machet; G Paintaud; L Machet
Journal:  Br J Dermatol       Date:  2010-04-12       Impact factor: 9.302

Review 3.  Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.

Authors:  Min S Park; Vinod Ravi; Dejka M Araujo
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

4.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

5.  Soft-tissue sarcomas of the head and neck.

Authors:  A M Freedman; H M Reiman; J E Woods
Journal:  Am J Surg       Date:  1989-10       Impact factor: 2.565

6.  Cutaneous angiosarcoma of the head and neck.

Authors:  D J Hodgkinson; E H Soule; J E Woods
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

Review 7.  Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors.

Authors:  H Willers; E B Hug; I J Spiro; J T Efird; A E Rosenberg; C C Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-10-15       Impact factor: 7.038

8.  Angiosarcoma of skin and soft tissue: a study of forty-four cases.

Authors:  J C Maddox; H L Evans
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

9.  Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.

Authors:  Bridget F Koontz; Edward F Miles; Mary Ann D Rubio; John F Madden; Samuel R Fisher; Richard L Scher; David M Brizel
Journal:  Head Neck       Date:  2008-02       Impact factor: 3.147

10.  Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.

Authors:  Wataru Tokuyama; Tetuo Mikami; Mikio Masuzawa; Isao Okayasu
Journal:  Hum Pathol       Date:  2009-11-13       Impact factor: 3.466
View more
  2 in total

1.  Comprehensive treatment of unresectable cardiac angiosarcoma: A case report and review of literature.

Authors:  Chao Wang; Min Shi; Chen Yang; Tao Ma; Jinling Jiang; Ying Liu; Wenqi Xi; Zhenggang Zhu; Jun Zhang
Journal:  Mol Clin Oncol       Date:  2017-08-24

2.  Angiosarcoma of the Head and Neck.

Authors:  Brandon Mullins; Trevor Hackman
Journal:  Int Arch Otorhinolaryngol       Date:  2015-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.